Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Details) - Schedule of antidilutive securities excluded from computation of diluted net loss per share

v3.22.2.2
Net Loss Per Share (Details) - Schedule of antidilutive securities excluded from computation of diluted net loss per share - shares
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Schedule Of Antidilutive Securities Excluded From Computation Of Diluted Net Loss Per Share Abstract        
Options to purchase common stock 1,165,397 822,457 1,165,397 822,457
Warrants to purchase common stock 4,784,193 4,784,193 4,784,193 4,784,193
Total 5,949,590 5,606,650 5,949,590 5,606,650